were washed with sat. aqueous NaS2O3 solution, then dried over magnesium sulfate. After evaporation of the solvent under reduced pressure, the crude product was purified by column chromatography. 6,7,8,9-Tetrabromo-4,11-bis((triisopropylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4 -b]phenazine 2 1 (250 mg, 474 µmol, 1 equiv.) and tetrabromoorthoquinone (241 mg, 569 µmol, 1.2 equiv.) were stirred for 32 h in 5.00 mL of DCM / AcOH (1:1) at room temperature. The mixture was poured into DI water and extracted with DCM. The organic phases were treated with sat. aqueous sodium bicarbonate and dried over magnesium sulfate. After evaporation of the solvent under reduced pressure, the crude product was purified by chromatography on silica using PE / DCM 9:1 -> 5:1 as eluent to give the product as a dark green crystalline solid (326 mg, 356 µmol, 75 %). M.p.: 258 °C. 1 
4,11-Bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl)-5,10-dihydro-[1,2,5]thiadiazolo[3,4-b]phenazine 3a-H2
Bis(benzonitrile)palladium(II) dichloride (16.8 mg, 43.7 µmol, 0.1 equiv.) was placed in a Schlenk tube and transferred into a glove-box under nitrogen atmosphere. 10.0 mL abs. THF were added followed by P(t-Bu)3 (17.7 mg, 87.5 µmol, 0.2 equiv.). The Schlenk tube was closed and taken outside the glove-box. Then, against a counter-flow of argon, 2 (400 mg, 437 µmol, 1 equiv.) and trimethyl((trimethylstannyl)-ethynyl)silane (1.37 g, 5.25 mmol, 12 equiv.) were added and the reaction mixture stirred at room temperature for 2.5 h. After adding DI water, extraction with DCM and drying of the organic phases over magnesium sulfate, the crude solution was filtered through a pad of silica. The solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica using PE / DCM 20:1 -> 10:1 -> 5:1 as eluent to give the product as a red solid (340 mg, 345 µmol, 79%). M.p.: 280 °C decomp.. 1 
4,11-Bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4-b]phenazine 3a
GP1 was applied to 3a-H2 (300 mg, 304 µmol, 1 equiv.) and MnO2 (265 mg, 3.04 mmol, 10 equiv.) in 20.0 mL DCM. The reaction mixture quickly turned from red to green. After 2 h at room temperature the reaction was worked up. Chromatography on silica using PE / DCM 10:1 -> 5:1 -> 3:1 as eluent gave the product as a green solid (287 mg, 292 µmol, 96%). M.p.: 265 °C. 1 
6,7,8,9-Tetrakis(3,3-dimethylbut-1-yn-1-yl)-4,11-bis((triisopropylsilyl)ethynyl)-5,10-dihydro-[1,2,5]thiadiazolo[3,4-b]phenazine

3b-H2
Bis(benzonitrile)palladium(II) dichloride (16.8 mg, 43.7 µmol, 0.1 equiv.) was placed in a Schlenk tube and transferred into a glove-box under nitrogen atmosphere. 10.0 mL abs. THF were added followed by P(t-Bu)3 (17.7 mg, 87.5 µmol, 0.2 equiv.). The Schlenk tube was closed and taken outside the glove-box. Then, against a counter-flow of argon, 2 (400 mg, 437 µmol, 1 equiv.) and (3,3-dimethylbut-1-yn-1-yl)trimethylstannane (1.29 g, 5.25 mmol, 12 equiv.) were added and the reaction mixture stirred at room temperature for 2.5 h.
After adding DI water, extraction with DCM and drying of the organic phases over magnesium sulfate, the crude solution was filtered through a pad of silica. The solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica using PE / DCM 9:1 -> 6:1 -> 4:1 as eluent to give the product as a red solid (349 mg, 378 µmol, 87%). M.p.: 298 °C decomp. 1 Fluorescence: λmax, em (hexane) = 532 nm.
6,7,8,9-Tetrakis(3,3-dimethylbut-1-yn-1-yl)-4,11-bis((triisopropylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4-b]phenazine 3b
GP1 was applied to 3b-H2 (500 mg, 543 µmol, 1 equiv.) and MnO2 (471 mg, 5.43 mmol, 10 equiv.) in 30.0 mL DCM. The reaction mixture quickly turned from red to green. After 2 h at room temperature the reaction was worked up. Chromatography on silica using PE / DCM 10:1 -> 5:1 -> 3:1 as eluent gave the product as a green solid (490 mg, 533 µmol, 98%). M.p.: 273 °C. 1 
1,4-Bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl)phenazine-2,3-diamine 4a
GP2 was applied to 3a (230 mg, 234 µmol, 1 equiv.) and SmI2 (28.1 mL, 2.81 mmol, 0.1 M in THF, 12 equiv.) in 10.0 mL abs. THF and 0.25 mL abs. MeOH. After workup the crude product was purified by chromatography on silica using PE / EE 20:1 -> 10:1 -> 5:1 as eluent to give the product as an orange solid (222 mg, 232 µmol, quant.). M.p.: 236. 1 6,7,8,9-Tetrakis(3,3-dimethylbut-1-yn-1-yl)-1,4-bis((triisopropylsilyl)ethynyl) 
phenazine-2,3-diamine 4b
GP2 was applied to 3b (240 mg, 261 µmol, 1 equiv.) and SmI2 (31.3 mL, 3.13 mmol, 0.1 M in THF, 12 equiv.) in 10.0 mL abs. THF and 0.25 mL abs. MeOH. After workup the crude product was purified by chromatography on silica using PE / EE 20:1 -> 10:1 as eluent to give the product as an orange solid (231 mg, 259 µmol, quant.). M.p.: 249 °C. 1 1,2,3,4-Tetrabromo-6,13-bis((triisopropylsilyl)ethynyl)-8,9,10,11-tetrakis((trimethylsilyl)ethynyl)-quinoxalino[2,3-b ]phenazine 7a 4a (56.0 mg, 58.6 µmol, 1 equiv.) and tetrabromoorthoquinone (49.7 mg, 117 µmol, 2 equiv.) were stirred for 16 h in 4.00 mL of DCM / AcOH (1:1) at room temperature. The mixture was poured into DI water and extracted with DCM. The organic phases were treated with sat. aqueous sodium bicarbonate and dried over magnesium sulfate. After evaporation of the solvent under reduced pressure, the crude product was purified by chromatography on silica using PE / DCM 20:1 -> 10:1 -> 5:1 as eluent to give the product as a brown solid (4.00 mg, 2.98 µmol, 5%). 1 6,7,8,9-Tetrabromo-4,11-bis((triisopropylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4- 11-bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl)-5,10-dihydro-[1,2,5]thiadiazolo[3,4-b 11-bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4-b ]phenazine 3a Figure S21 . 1 6,7,8,9-tetrakis(3,3-dimethylbut-1-yn-1-yl)-4,11-bis((triisopropylsilyl)ethynyl)-5,10-dihydro-[1,2,5]thiadiazolo[3,4 
NMR-Spectra
4,
-b]phenazine
3b-H2 Figure S23 . 1 6,7,8,9-tetrakis(3,3-dimethylbut-1-yn-1-yl)-4,11-bis((triisopropylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4- 4-bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl) 6,7,8,9-tetrakis(3,3-dimethylbut-1-yn-1-yl)-1,4-bis((triisopropylsilyl)ethynyl) phenazine-2,3-diamine 4b Figure S29 . 1 2,3,5,12-tetrakis((triisopropylsilyl)ethynyl)-7,8,9,10-tetrakis((trimethylsilyl)ethynyl)-1,2-dihydropyrazino[2,3-b ]phenazine 6 Figure S31 . 1 H NMR (600 MHz, CDCl3) of 6. Figure S32 . 13 1,2,3,4-tetrabromo-6,13-bis((triisopropylsilyl)ethynyl)-8,9,10,11-tetrakis((trimethylsilyl)ethynyl)-quinoxalino[2,3-b ]phenazine 7a Figure S33 . 1 H NMR (600 MHz, CDCl3) of 7a. Figure S34 . 13 1,2,3,4-tetrabromo-8,9,10,11-tetrakis(3,3-dimethylbut-1-yn-1-yl)-6,13-bis((triisopropylsilyl)ethynyl)-5,14-dihydroquinoxalino-[2,3-b ]phenazine 7b-H2 Figure S35 . 1 1,2,3,4,8,9,10,11-octakis(3,3-dimethylbut-1-yn-1-yl)-6,13-bis((triisopropylsilyl)ethynyl)-quinoxalino[2,3-b ]phenazine 8 Figure S39 . 1 Figure S41 . IR-Spectrum of 2. Figure S42 . IR-Spectrum of 3a-H2. Figure S43 . IR-Spectrum of 3a. 7,8,9-tetrakis(3,3-dimethylbut-1-yn-1-yl)-4,11-bis((triisopropylsilyl)ethynyl)-5,10-dihydro-[1,2,5]thiadiazolo[3,4-b ]phenazine 3b-H2 Figure S44 . IR-Spectrum of 3b-H2. Figure S45 . IR-Spectrum of 3b. Figure S46 . IR-Spectrum of 4a. Figure S47 . IR-Spectrum of 4b. 3,5,12-tetrakis((triisopropylsilyl)ethynyl)-7,8,9,10-tetrakis((trimethylsilyl)ethynyl)-1,2-dihydropyrazino[2,3 -b]phenazine 6 Figure S48 . IR-Spectrum of 6.
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6,7,8,9-Tetrabromo-4,11-bis((triisopropylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4-b]phenazine 2
4,11-bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl)-5,10-dihydro-[1,2,5]thiadiazolo[3,4-b]phenazine 3a-H2
4,11-bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4-b]phenazine 3a
6,
6,7,8,9-tetrakis(3,3-dimethylbut-1-yn-1-yl)-4,11-bis((triisopropylsilyl)ethynyl)-[1,2,5]thiadiazolo[3,4-b]phenazine 3b
1,4-bis((triisopropylsilyl)ethynyl)-6,7,8,9-tetrakis((trimethylsilyl)ethynyl)phenazine-2,3-diamine 4a
6,7,8,9-tetrakis(3,3-dimethylbut-1-yn-1-yl)-1,4-bis((triisopropylsilyl)ethynyl)phenazine-2,3-diamine 4b
2,
1,2,3,4-tetrabromo-6,13-bis((triisopropylsilyl)ethynyl)-8,9,10,11-tetrakis((trimethylsilyl)ethynyl)-quinoxalino[2,3-b]phenazine
7a Figure S49 . IR-Spectrum of 7a. 2,3,4-tetrabromo-8,9,10,11-tetrakis(3,3-dimethylbut-1-yn-1-yl)-6,13-bis((triisopropylsilyl)ethynyl)-5,14-dihydroquinoxalino-[2,3-b ]phenazine 7b-H2 Figure S50 . IR-Spectrum of 7b-H2. 2,3,4,8,9,10,11-octakis(3,3-dimethylbut-1-yn-1-yl)-6,13-bis((triisopropylsilyl)ethynyl)-5,14-dihydroquinoxalino[2,3 b]phenazine 8-H2 Figure S51 . IR-Spectrum of 8-H2. 2,3,4,8,9,10,11-octakis(3,3-dimethylbut-1-yn-1-yl)-6,13-bis((triisopropylsilyl)ethynyl)-quinoxalino[2,3-b ]phenazine 8 Figure S52 . IR-Spectrum of 8. 2,3,5,12-tetrakis((triisopropylsilyl)ethynyl)-7,8,9,10-tetrakis((trimethylsilyl)ethynyl)-1,2-dihydropyrazino[2,3-b Figure S53 . Crystal data and structure of 6 (CCDC 1947891). 2,3,4,8,9,10,11-octakis(3,3-dimethylbut-1-yn-1-yl)-6,13-bis((triisopropylsilyl) 
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